MFSD2A

Across TCGA pan-cancer cohorts, MFSD2A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MFSD2A data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MFSD2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MFSD2A expression acts as an unfavorable survival marker.

LIHC, LUAD, and SKCM are the cancer types where MFSD2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.191	0.719	.001	35	view →
LUAD	OS	Median	All	0.158	0.835	<.001	30	view →
SKCM	DFS	Median	All	0.254	0.763	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MFSD2A–LIHC (OS)

Open the LIHC breakdown →